Prolanta(Oncolix)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameProlanta(Oncolix)
Drug Alias Nameanti-HER2 agentProlactin receptor antagonistProlactin receptor antagonist/anti-HER2 agent
ClassificationBiologics
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsProlactin receptor modulators
TargetsProlactin receptorReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOncolix Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOncolix Inc
Active IndicationsN/A
Inactive IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A